Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 - 40 Advanced Cancer Patients

Stock Information for Propanc Biopharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Propanc Biopharma Inc.

Propanc Biopharma Publishes Evaluation of Recombinant Trypsinogen & Chymotrypsinogen in Peer Reviewed Journal
Propanc Biopharma Signs MOU with Avance Clinical Pty Ltd
Propanc Biopharma Initiates $5.0 Million Share Repurchase Program
Propanc Biopharma's CEO Tours European CDMO & Plans for GMP Production of PRP for Phase 1b, FIH Study
ShareStructure.io Announces Investor Education Platform on Public Company Financing Activity.
Propanc Biopharma Authorizes $5.0 Million Share Repurchase Program
Propanc Biopharma's CEO Attends Keynote Address, "Rejuvenation and Health: Science for an Ageing Society," at the University of Granada, Spain
Propanc Biopharma's CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.